Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that selectively binds to and inhibits the neonatal fragment crystallizable receptor, which is in Phase IIa clinical trials for the treatment of myasthenia gravis and thyroid eye disease, as well as completed initiation of Phase II clinical trials for the treatment of warm autoimmune hemolytic anemia. The company was incorporated in 2018 is headquartered in New York, New York. Immunovant, Inc. is a subsidiary of Roivant Sciences Ltd.

Immunovant, Inc.

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

NEW YORK, AUG. 11, 2025 (GLOBE NEWSWIRE) -- IMMUNOVANT, INC. (NASDAQ: IMVT), A CLINICAL-STAGE IMMUNOLOGY COMPANY DEDICATED TO ENABLING NORMAL LIVES FOR PEOPLE WITH AUTOIMMUNE DISEASES, TODAY REPORTED CORPORATE UPDATES AND FINANCIAL RESULTS FOR THE QUARTER ENDED JUNE 30, 2025.

IMMUNOVANT PROVIDES CORPORATE UPDATES AND REPORTS FINANCIAL RESULTS FOR THE QUARTER ENDED JUNE 30, 2025

IMMUNOVANT'S NEW MANAGEMENT TEAM IS FOCUSED ON RAPID CLINICAL EXECUTION FOR THE SIX ANNOUNCED INDICATIONS FOR IMVT-1402, INCLUDING A SECOND POTENTIALLY REGISTRATIONAL STUDY IN GRAVES' DISEASE (GD) AND A POTENTIALLY REGISTRATIONAL STUDY IN SJGREN'S DISEASE (SJD), BOTH EXPECTED TO START IN SUMMER 2025 POSITIVE DATA FROM FIRST-GENERATION BATOCLIMAB TRIALS IN MYASTHENIA GRAVIS (MG) AND CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY (CIDP) DEMONSTRATED THAT DEEPER IGG REDUCTIONS CORRELATED WITH IMPROVED CLINICAL OUTCOMES ACROSS A RANGE OF ASSESSMENTS AND TIMEPOINTS SUGGESTING A POTENTIAL BEST-IN-CLASS EFFICACY PROFILE FOR IMVT-1402 CURRENT CASH BALANCE PROVIDES RUNWAY FOR ANNOUNCED INDICATIONS THROUGH GD READOUT EXPECTED IN 2027 NEW YORK, MAY 29, 2025 (GLOBE NEWSWIRE) -- IMMUNOVANT, INC. (NASDAQ: IMVT), A CLINICAL-STAGE IMMUNOLOGY COMPANY DEDICATED TO ENABLING NORMAL LIVES FOR PEOPLE WITH AUTOIMMUNE DISEASES, TODAY REPORTED CORPORATE UPDATES AND FINANCIAL RESULTS FOR ITS FOURTH QUARTER AND FISCAL YEAR ENDED MARCH 31, 2025. RECENT HIGHLIGHTS AND UPCOMING MILESTONES: IN APRIL 2025, IMMUNOVANT ANNOUNCED CHANGES TO ITS LEADERSHIP TEAM AS PART OF A BROADER STRATEGIC TRANSITION WITH ROIVANT INCREASING OPERATIONAL INVOLVEMENT AND OVERSIGHT OF IMMUNOVANT.

IMMUNOVANT PROVIDES CORPORATE UPDATES AND REPORTS FINANCIAL RESULTS FOR THE FOURTH QUARTER AND FISCAL YEAR ENDED MARCH 31, 2025

NEW YORK, APRIL 21, 2025 (GLOBE NEWSWIRE) -- IMMUNOVANT,INC.(NASDAQ:IMVT), A CLINICAL-STAGE IMMUNOLOGY COMPANY DEDICATED TO ENABLING NORMAL LIVES FOR PEOPLE WITH AUTOIMMUNE DISEASES, TODAY ANNOUNCED NEXT PHASE OF GROWTH INCLUDING CHANGES TO ITS LEADERSHIP TEAM AND THE EXPANDED DEVELOPMENT OF IMVT-1402 INTO TWO NEW INDICATIONS, SJD AND CLE.

IMMUNOVANT ANNOUNCES NEXT PHASE OF GROWTH WITH ROIVANT INCLUDING CHANGES TO ITS LEADERSHIP TEAM AND ADDITIONAL INDICATIONS SJGREN'S DISEASE (SJD) AND CUTANEOUS LUPUS ERYTHEMATOSUS (CLE) FOR IMVT-1402

NEW YORK, MARCH 19, 2025 (GLOBE NEWSWIRE) -- IMMUNOVANT, INC. (NASDAQ: IMVT), A CLINICAL-STAGE IMMUNOLOGY COMPANY DEDICATED TO ENABLING NORMAL LIVES FOR PEOPLE WITH AUTOIMMUNE DISEASES, TODAY REPORTED TOPLINE RESULTS FROM ITS PHASE 3 STUDY OF BATOCLIMAB IN MG AND INITIAL RESULTS FROM PERIOD 1 OF ITS PHASE 2B STUDY IN CIDP.

IMMUNOVANT ANNOUNCES POSITIVE RESULTS FOR BATOCLIMAB MYASTHENIA GRAVIS (MG) AND CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY (CIDP) STUDIES

NEW YORK, MARCH 18, 2025 (GLOBE NEWSWIRE) -- IMMUNOVANT, INC. (NASDAQ: IMVT), A CLINICAL-STAGE IMMUNOLOGY COMPANY DEDICATED TO ENABLING NORMAL LIVES FOR PEOPLE WITH AUTOIMMUNE DISEASES, TODAY ANNOUNCED THAT IT WILL HOST AN INVESTOR WEBCAST ON WEDNESDAY, MARCH 19TH AT 8:00 A.M. ET TO REVIEW RESULTS FROM ITS PHASE 3 STUDY OF BATOCLIMAB IN MG AND INITIAL RESULTS FROM ITS PHASE 2B STUDY IN CIDP.

IMMUNOVANT TO HOST INVESTOR WEBCAST AT 8:00 AM ET ON WEDNESDAY, MARCH 19 TO REVIEW RESULTS FROM BATOCLIMAB MYASTHENIA GRAVIS (MG) AND CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY (CIDP) PROGRAMS

NEW YORK, FEB. 06, 2025 (GLOBE NEWSWIRE) -- IMMUNOVANT, INC. (NASDAQ: IMVT), A CLINICAL-STAGE IMMUNOLOGY COMPANY DEDICATED TO ENABLING NORMAL LIVES FOR PEOPLE WITH AUTOIMMUNE DISEASES, TODAY REPORTED FINANCIAL RESULTS FOR ITS FISCAL THIRD QUARTER ENDED DECEMBER 31, 2024.

IMMUNOVANT REPORTS FINANCIAL RESULTS FOR THE QUARTER ENDED DECEMBER 31, 2024

NEW YORK , JAN. 24, 2025 /PRNEWSWIRE/ -- KUEHN LAW, PLLC, A SHAREHOLDER LITIGATION LAW FIRM, IS INVESTIGATING WHETHER CERTAIN OFFICERS AND DIRECTORS OF IMMUNOVANT, INC. (NASDAQ: IMVT) BREACHED THEIR FIDUCIARY DUTIES TO SHAREHOLDERS. THE INVESTIGATION CONCERNS POTENTIAL SELF-DEALING.

KUEHN LAW ENCOURAGES INVESTORS OF IMMUNOVANT, INC. TO CONTACT LAW FIRM

PRESENTS CURRENT TREATMENT PRACTICES, EMERGING DRUGS, MARKET SHARE OF INDIVIDUAL THERAPIES, AND FCRN INHIBITOR MARKET SIZE FROM 2020 TO 2034 PRESENTS CURRENT TREATMENT PRACTICES, EMERGING DRUGS, MARKET SHARE OF INDIVIDUAL THERAPIES, AND FCRN INHIBITOR MARKET SIZE FROM 2020 TO 2034

FCRN INHIBITOR MARKET SIZE, TARGET POPULATION, COMPETITIVE LANDSCAPE & FORECAST TO 2034 - IMMUNOVANT ADVANCES FCRN INHIBITOR PIPELINE WITH PROMISING RESULTS AND FDA GREEN LIGHT FOR PIVOTAL TRIAL

NEW YORK, NOV. 07, 2024 (GLOBE NEWSWIRE) -- IMMUNOVANT, INC. (NASDAQ: IMVT), A CLINICAL-STAGE IMMUNOLOGY COMPANY DEDICATED TO ENABLING NORMAL LIVES FOR PEOPLE WITH AUTOIMMUNE DISEASES, TODAY REPORTED DEVELOPMENT UPDATES AND FINANCIAL RESULTS FOR ITS FISCAL SECOND QUARTER ENDED SEPTEMBER 30, 2024.

IMMUNOVANT PROVIDES DEVELOPMENT UPDATES AND REPORTS FINANCIAL RESULTS FOR THE QUARTER ENDED SEPTEMBER 30, 2024

NEW YORK, OCT. 29, 2024 (GLOBE NEWSWIRE) -- IMMUNOVANT, INC. (NASDAQ: IMVT), A CLINICAL-STAGE IMMUNOLOGY COMPANY DEDICATED TO ENABLING NORMAL LIVES FOR PEOPLE WITH AUTOIMMUNE DISEASES, TODAY ANNOUNCED THAT DATA FROM THE PHASE 2A TRIAL OF BATOCLIMAB IN GRAVES' DISEASE WILL BE THE SUBJECT OF AN ORAL PRESENTATION OF A LATE-BREAKING ABSTRACT ACCEPTED FOR THE 2024 AMERICAN THYROID ASSOCIATION (ATA) ANNUAL MEETING BEING HELD OCTOBER 30 TO NOVEMBER 3, 2024, IN CHICAGO, ILLINOIS. NEW DATA HIGHLIGHTING BOTH THYROID-SPECIFIC AND EXTRATHYROIDAL MANIFESTATIONS OF GRAVES' DISEASE WILL BE PRESENTED.

IMMUNOVANT ANNOUNCES ORAL PRESENTATION OF LATE BREAKING ABSTRACT FOR PHASE 2 GRAVES' DISEASE CLINICAL DATA AT THE 2024 AMERICAN THYROID ASSOCIATION (ATA) ANNUAL MEETING

NEW YORK, SEPT. 09, 2024 (GLOBE NEWSWIRE) -- IMMUNOVANT, INC. (NASDAQ: IMVT), A CLINICAL-STAGE IMMUNOLOGY COMPANY DEDICATED TO ENABLING NORMAL LIVES FOR PEOPLE WITH AUTOIMMUNE DISEASES, TODAY REPORTED POSITIVE RESULTS FROM THE PHASE 2A TRIAL OF BATOCLIMAB IN GRAVES' DISEASE. IMMUNOVANT ALSO DISCLOSED DATA FROM SEVERAL PROPRIETARY MARKET RESEARCH STUDIES THAT SHOWED A CONSISTENT UNMET NEED AMONG ATD TREATED PATIENTS WHO ARE INTOLERANT TO, UNCONTROLLED ON OR RELAPSED AFTER ATDS. FINALLY, IMMUNOVANT ALSO ANNOUNCED ALIGNMENT WITH THE U.S. FOOD & DRUG ADMINISTRATION (FDA) AND INVESTIGATIONAL NEW DRUG APPLICATION (IND) CLEARANCE WITH INITIATION OF A PIVOTAL TRIAL OF IMVT-1402 IN GD EXPECTED BY DECEMBER 31, 2024.

Immunovant, Inc.

IMVT

Price

Financials Overview

Financial Reports

No items found.

Press Releases

Immunovant, Inc.

IMVT.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financials Overview

Financial Reports

No items found.

Press Releases

IMVT